Atropos Health, a Palo Alto, CA-based company which specializes in evidence-based healthcare, received an undisclosed amount in strategic financing.
The round saw participation from Presidio Ventures, Samsung Next, a venture arm of Samsung Electronics, Gaingels, Audere Capital, and others.
The company intends to use the funds to accelerate commercial and development opportunities outside the U.S., using its proprietary technology and approach. Initial focus centers on key customers in Japan and Brazil.
Led by CEO Dr. Brigham Hyde, Atropos Health is the developer of Atropos Evidence™ Platform, a catalyst for evidence generation from a network of real world data. Healthcare organizations, life science companies, and other clinicians and researchers leverage the cloud-based platform to close evidence gaps from bench to bedside, elevate clinical outcomes with data-driven care, expedite research, and more. Its offerings are based upon peer-reviewed publications, clinician users, clinical use, and clinical expertise. We aim to transform healthcare with timely, relevant real-world evidence.
In addition to the strategic investment, the company has added partnerships with Analitica, Syndesis Health, DVX, and Project 360 LTD, to provide a critical footprint of in-market data integration support and channel distribution across Asia, South America and the Middle East.
FinSMEs
22/09/2023